Financings In Brief
This article was originally published in The Gray Sheet
Executive Summary
ReGen Biologics raises funds for Menaflex launch: U.S. launch of collagen knee cartilage repair implant in February will be supported in part by proceeds from a $10 million private placement of common stock, announced Jan. 21. The Hackensack, N.J., firm completed the first $7 million in funding on Jan. 16 and will raise $3 million more in a planned second stage, ReGen explains. The financing round was led by Sanderling Venture Partners. Menaflex gained 510(k) clearance in December (1"The Gray Sheet" Jan. 5, 2009, p. 24)
You may also be interested in...
Avantis Medical Systems’ Third Eye Retroscope
Expanded indication for the colon cancer detection tool gains 510(k) clearance, supporting a claim for increased detection of cancerous and pre-cancerous polyps in the colon when used in conjunction with colonoscopy, the firm announces Feb. 17. The device, initially cleared in April 2007, provides physicians a backward view of the colon that complements the forward view of the colonoscope to help them visualize blind spots in the colon where cancers may be hiding, the firm explains. The Sunnyvale, Calif.-based company recently raised $10 million in a "Series C" financing to help fund a rollout of the device this year, as well as to establish U.S. centers of excellence to facilitate the launch, to collect additional data supporting clinical utility, and for sales and marketing efforts (1"The Gray Sheet" Jan. 26, 2009, p.20)
Avantis Medical Systems’ Third Eye Retroscope
Expanded indication for the colon cancer detection tool gains 510(k) clearance, supporting a claim for increased detection of cancerous and pre-cancerous polyps in the colon when used in conjunction with colonoscopy, the firm announces Feb. 17. The device, initially cleared in April 2007, provides physicians a backward view of the colon that complements the forward view of the colonoscope to help them visualize blind spots in the colon where cancers may be hiding, the firm explains. The Sunnyvale, Calif.-based company recently raised $10 million in a "Series C" financing to help fund a rollout of the device this year, as well as to establish U.S. centers of excellence to facilitate the launch, to collect additional data supporting clinical utility, and for sales and marketing efforts (1"The Gray Sheet" Jan. 26, 2009, p.20)
Third Time Is The Charm For ReGen’s Knee Repair Collagen Scaffold
ReGen Biologics plans a February U.S. launch of its Menaflex collagen knee cartilage repair product at the 2009 American Academy of Orthopedic Surgeons meeting in Las Vegas now that FDA has signed off on the product after several years of resistance